Your browser doesn't support javascript.
loading
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
Murphy, Sabina A; Pedersen, Terje R; Gaciong, Zbigniew A; Ceska, Richard; Ezhov, Marat V; Connolly, Derek L; Jukema, J Wouter; Toth, Kalman; Tikkanen, Matti J; Im, Kyungah; Wiviott, Stephen D; Kurtz, Christopher E; Honarpour, Narimon; Giugliano, Robert P; Keech, Anthony C; Sever, Peter S; Sabatine, Marc S.
Afiliação
  • Murphy SA; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Masschusetts.
  • Pedersen TR; Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway.
  • Gaciong ZA; Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw, Warsaw, Poland.
  • Ceska R; Center for Preventive Cardiology, 3rd Internal Medicine Clinic, University General Hospital and Charles University 1st Medical Faculty, Prague, Czech Republic.
  • Ezhov MV; National Cardiology Research Center, Moscow, Russia.
  • Connolly DL; Birmingham City and Sandwell Hospitals and the Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, England.
  • Jukema JW; Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Toth K; First Department of Medicine, University of Pecs, Medical School, Pecs, Hungary.
  • Tikkanen MJ; Folkhälsan Research Center, University of Helsinki, Helsinki, Finland.
  • Im K; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Masschusetts.
  • Wiviott SD; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Masschusetts.
  • Kurtz CE; Amgen, Thousand Oaks, California.
  • Honarpour N; Amgen, Thousand Oaks, California.
  • Giugliano RP; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Masschusetts.
  • Keech AC; Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Sever PS; Imperial College London, London, England.
  • Sabatine MS; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Masschusetts.
JAMA Cardiol ; 4(7): 613-619, 2019 07 01.
Article em En | MEDLINE | ID: mdl-31116355
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Anticorpos Monoclonais Humanizados / Inibidores de PCSK9 / Anticolesterolemiantes Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Anticorpos Monoclonais Humanizados / Inibidores de PCSK9 / Anticolesterolemiantes Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article